Top 10 Innovative Pharmaceutical Advances in 2022
1. Novavax COVID-19 Vaccine
The Novavax COVID-19 vaccine, known as NVX-CoV2373, was granted emergency use authorization (EUA) by the FDA in late 2021. It is a protein-based vaccine that uses recombinant nanoparticle technology, making it a valuable addition to the global vaccine arsenal.
2. Atezolizumab for lung cancer treatment
Atezolizumab, a monoclonal antibody, was approved by the FDA for the treatment of certain types of lung cancer. It targets the protein PD-L1, helping the body’s immune system attack cancer cells more effectively.
3. Ustekinumab for psoriatic arthritis
Ustekinumab, a biologic medication, was approved for the treatment of psoriatic arthritis. It is an interleukin-12/23 inhibitor, helping to reduce inflammation and improve joint pain and swelling in patients with psoriatic arthritis.
4. Oral semaglutide for type 2 diabetes management
Oral semaglutide was approved by the FDA for the treatment of type 2 diabetes. It is a GLP-1 receptor agonist that helps regulate blood sugar levels, promoting weight loss and improved glycemic control in patients with type 2 diabetes.
5. Luspatercept for anemia in patients with myelodysplastic syndromes and beta-thalassemia
Luspatercept, a first-in-class erythroid maturation agent, was approved by the FDA for the treatment of anemia in patients with myelodysplastic syndromes and beta-thalassemia. It helps stimulate red blood cell production and alleviate anemia symptoms.
6. Ibrutinib for the treatment of mantle cell lymphoma
Ibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, was approved by the FDA for the treatment of mantle cell lymphoma. It helps inhibit the growth of cancer cells and improve overall survival in patients with this type of lymphoma.
7. Enasidenib for acute myeloid leukemia
Enasidenib, an IDH2 inhibitor, was approved by the FDA for the treatment of acute myeloid leukemia (AML) with an IDH2 mutation. It helps promote differentiation and survival of immature blood cells, improving outcomes for patients with this type of AML.
8. Bempegliflozin for heart failure with reduced ejection fraction
Bempegliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, was approved by the FDA for the treatment of heart failure with reduced ejection fraction. It helps reduce the risk of hospitalization for heart failure and cardiovascular death in patients with this condition.
9. Sarilumab for rheumatoid arthritis
Sarilumab, an interleukin-6 receptor inhibitor, was approved by the FDA for the treatment of moderate to severe rheumatoid arthritis. It helps reduce
